Local sclerotherapy with polydocanol (Aethoxysklerol®) for the treatment of epistaxis in Rendu-Osler-Weber or hereditary hemorrhagic telangiectasia (HHT): 15 years of experience

Rhinology

Volumn 50, Issue 1, 2012, Pages 80-86

  Morais, Darío ^a   Millás, Teresa ^a   Zarrabeitia, Roberto ^b   Botella, Luisa M ^c   Almaraz, Ana ^d  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b HOSPITAL SIERRALLANA   (Spain)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^d UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Epistaxis; Hereditary hemorrhagic telangiectasia; Polydocanol; Rendu Osler Weber; Submucosal injection

Indexed keywords

MACROGOL DERIVATIVE; POLIDOCANOL; SCLEROSING AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; EPISTAXIS; FEMALE; HUMAN; MALE; MIDDLE AGED; RENDU OSLER WEBER DISEASE; SCLEROTHERAPY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; EPISTAXIS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; SCLEROSING SOLUTIONS; SCLEROTHERAPY; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; YOUNG ADULT;

EID: 84862654480     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/Rhino11.142     Document Type: Article

References (22)

1. Fontalba A, Fernandez-L A, Garcia-Alegria, E, et al. Mutation study of Spanish patients with Hereditary Hemorrhagic Telangiectasia. BMC Med Genet. 2008; 9: 75-86.
2. Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, et al. Blood outgrowth endotelial cells from Hereditary Haemorragic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res. 2005; 68: 235-248.
3. Pérez del Molino A, Zarrabeitia R, Fernández A. Telangiectasia Hemorragica Hereditaria. Med Clin (Barc). 2005; 124: 583-587.
4. Kjelsen AD, Vase P, Green A. Hereditary Haemorrhagic Telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med. 1999; 245: 31-39.
5. Jessurun GA, Kamphuis DJ, Van der Zande FH, Nossent JC. Cerebral arteriovenous malformations in the Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arteriovenous malformations. Clin Neurol Neurosurg. 1993; 95: 193-198.
6. Cole SG, Begbie ME, Wallace GM, Shovlin CL. A new locus for hereditay haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet. 2005; 42: 577-582.
7. Bayrak-Toydemir P, Mcdonald J, Akarsu N, et al. Fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet. 2006; 140: 2155-2162.
8. Bergler W, Sadick H, Götte K, Riedel F, Hörmann K. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol. 2002; 111: 222-228.
9. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000; 91: 66-67.
10. Ramirez B, Morais D, Condado MA, Marcos M, Martin G, Poncela M. Una nueva sustancia esclerosante en el tratamiento de la enfermedad de Rendu-osler-Weber. Acta Otorrinolaring Esp. 2000; 51: 36-39.
11. Morais D, Ramirez B, Santos J. El tratamiento local esclerosante con Aethoxysklerol en la patología ORL: Enfermedad de Rendu-Osler, Granulomas, Angiomas. Acta Otorrinolaring Esp. 2002; 53: 658-661.
12. Martin H, Martin C. Les injections de cole ded fibrine dans les epistaxis graves et la malade de Rendu-Osler. Ann Oto-Laring parís. 1984; 101: 561-563.
13. Jankowski R, Beaudouin E, Kanny G, Wayoff M, Moneret-Vautrin DA. Accidents d'hypersensibilité a la thrombine, consécutifs a l'emploi de colles biologiques. Ann Otol-Laryng. (Paris) 1992; 109: 95-99.
14. Borsik M, Herbreteau D, Deffrennes D, et al. Le traitment des épistaxis de la maldie de Rendu-Osler par injection intramuqueuse d'Ethibloc. Ann Oto-Laryng (Paris). 1992; 109: 273-276.
15. ® injections. J Neuroradiol. 2004; 31: 110-115.
16. Faughnan ME, Palda VA, Garcia-Tsao G, et al. International Guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. J Med Genet. doi:10.1136/jmg.2009.069013.
17. Zarrabeitia R, Albiñana V, Salcedo M, Señaris-Gonzalez B, Fernandez-Forcelledo, JL, Botella LM. A review on clinical management and pharmacological therapy on Hereditary Haemorrhagic Telangiectasia (HHT). Curr Vasc Pharmacol. 2010; 8: 473-481.
18. Morales-Angulo C, Perez del Molino A, Zarrabeitia R, Fernandez A, Sanz-Rodriguez F, Botella LM. Tratamiento de las epistaxis en la telangiectasia hemorrágica hereditaria (enfermedad de Rendu-osler-Weber) con ácido tranexámico. Acta Otorrinolaringol Esp. 2007; 58: 129-132.
19. Sadick H, Naim R, Oulmi J, Hörmann K, Bergler W. Plasma surgery and topical estriol: effects on the nasal mucosa and longterm results in patients with Osleŕs disease. Otolaryngol Head Neck Surg. 2003; 129: 233-238.
20. Tomassin J-M, Dessi P, Ferman C, Dauvin J-B, Bailhache A. Surgery in the septal perforation, in Encyclopedie Medico-Chirurgicale: Otorhinolaryngological Surgery. E-46-135.
21. Saunders WH. Septal dermoplasty for control of nose bleeds caused by hereditary hemorrhagic telangiectasia or septal perforations. Trans Am Acad Ophtalmol Otolaryngol. 1960; 64: 500-506.
22. Lund VJ, Howard DJ. Closure of the nasal cavities in the treatment of refractory hereditary hemorrhagic telangiectasia. J laryngol Otol. 1997; 109: 95-99.